Stay updated on Nivolumab Combo in Early Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in Early Lung Cancer Clinical Trial page.

Latest updates to the Nivolumab Combo in Early Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page revision tag was updated from v3.5.2 to v3.5.3, indicating an administrative update to the record. This does not alter the study details or information presented to users.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedPage revision updated to v3.5.0 (replacing v3.4.3).SummaryDifference0.0%

- Check56 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check70 days agoChange DetectedThe study record now shows Terminated due to slow accrual and lack of funding, and results have been posted. The summary also includes the Major Pathologic Response (mpCR) definition and related outcome measures.SummaryDifference3%

- Check84 days agoChange DetectedAdded Revision: v3.4.2. The prior government funding/status notice (Revision: v3.4.1) was removed.SummaryDifference0.4%

Stay in the know with updates to Nivolumab Combo in Early Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Early Lung Cancer Clinical Trial page.